UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 6 von 1615
Datensatz exportieren als...
BibTeX
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Cancer, 2016-11, Vol.122 (21), p.3354-3362
Shoushtari, Alexander N.
Munhoz, Rodrigo R.
Kuk, Deborah
Ott, Patrick A.
Johnson, Douglas B.
Tsai, Katy K.
Rapisuwon, Suthee
Eroglu, Zeynep
Sullivan, Ryan J.
Luke, Jason J.
Gangadhar, Tara C.
Salama, April K. S.
Clark, Varina
Burias, Clare
Puzanov, Igor
Atkins, Michael B.
Algazi, Alain P.
Ribas, Antoni
Wolchok, Jedd D.
Postow, Michael A.
2016
Details
Autor(en) / Beteiligte
Shoushtari, Alexander N.
Munhoz, Rodrigo R.
Kuk, Deborah
Ott, Patrick A.
Johnson, Douglas B.
Tsai, Katy K.
Rapisuwon, Suthee
Eroglu, Zeynep
Sullivan, Ryan J.
Luke, Jason J.
Gangadhar, Tara C.
Salama, April K. S.
Clark, Varina
Burias, Clare
Puzanov, Igor
Atkins, Michael B.
Algazi, Alain P.
Ribas, Antoni
Wolchok, Jedd D.
Postow, Michael A.
Titel
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Ist Teil von
Cancer, 2016-11, Vol.122 (21), p.3354-3362
Ort / Verlag
United States
Erscheinungsjahr
2016
Link zum Volltext
Quelle
Electronic Journals Library
Beschreibungen/Notizen
BACKGROUND Therapeutic antibodies against programmed cell death receptor 1 (PD‐1) are considered front‐line therapy in metastatic melanoma. The efficacy of PD‐1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. METHODS A multi‐institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator‐assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression‐free survival and overall survival were assessed using the Kaplan‐Meier method. RESULTS Sixty individuals were identified, including 25 (42%) with acral melanoma and 35 (58%) with mucosal melanoma. Fifty‐one patients (85%) had received previous therapy, including 77% who had previously received ipilimumab. Forty patients (67%) received pembrolizumab at a dose of 2 mg/kg or 10 mg/kg, and 20 (33%) received nivolumab at a doses ranging from 0.3 to 10 mg/kg every 2 to 3 weeks. The objective response rate was 32% (95% confidence interval, 15%‐54%) in patients with acral melanoma and 23% (95% confidence interval, 10%‐40%) in those with mucosal melanoma. After a median follow‐up of 20 months in the acral melanoma group and 10.6 months in the mucosal melanoma group, the median progression‐free survival was 4.1 months and 3.9 months, respectively. Only 2 patients (3%) discontinued treatment because of toxicity. CONCLUSIONS Response rates to PD‐1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD‐1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354–3362. © 2016 American Cancer Society. The objective response rate of programmed cell death receptor 1 (PD‐1)–based therapy in patients with acral and mucosal melanoma is 32% and 23%, respectively, which is similar to published rates in cutaneous melanoma. These data support the routine use of PD‐1–based therapy for patients with these rare melanoma subtypes. See also pages 000‐000 and 000‐000.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.30259
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5134420
Format
–
Schlagworte
acral melanoma
,
Adult
,
Aged
,
Aged, 80 and over
,
Antibodies, Monoclonal - administration & dosage
,
Antibodies, Monoclonal, Humanized - administration & dosage
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
anti‐programmed cell death receptor 1 (anti‐PD‐1)
,
Brain Neoplasms - drug therapy
,
Brain Neoplasms - immunology
,
Brain Neoplasms - secondary
,
Female
,
Follow-Up Studies
,
Humans
,
immunotherapy
,
Liver Neoplasms - drug therapy
,
Liver Neoplasms - immunology
,
Liver Neoplasms - secondary
,
Male
,
Melanoma - drug therapy
,
Melanoma - immunology
,
Melanoma - pathology
,
Middle Aged
,
mucosal melanoma
,
Mucous Membrane - drug effects
,
Mucous Membrane - pathology
,
Neoplasm Staging
,
Nivolumab
,
pembrolizumab
,
Prognosis
,
Programmed Cell Death 1 Receptor - antagonists & inhibitors
,
Programmed Cell Death 1 Receptor - immunology
,
Retrospective Studies
,
Skin Neoplasms - drug therapy
,
Skin Neoplasms - immunology
,
Skin Neoplasms - pathology
,
Survival Rate
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX